Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE).
Researchers
Giovanna Muscogiuri, Manuela Albertelli, Giorgio Arnaldi, Luigi Barrea, Giuseppe Bellastella, Marco Bonomi, Marina Caputo, Massimiliano Caprio, Angelo Cignarelli, Ludovico Di Gioia, Francesco Frasca, Davide Ferrari, Alessandra Gambineri, Valentina Gasco, Federico Gatto, Annalisa Giandalia, Roberta Giordano, Marco Infante, Andrea Isidori, Pasqualino Malandrino, Gianluca Occhi, Rosario Pivonello, Nunzia Prencipe, Flavia Prodam, Chiara Simeoli, Ludovica Verde, Linda Vignozzi, Salvatore Cannavò, Francesco Giorgino, Annamaria Colao, Gianluca Aimaretti, Diego Ferone, Sebastio Perrini
Abstract
Dyslipidemias are highly prevalent metabolic disturbances and represent a major driver of atherosclerotic cardiovascular disease. Beyond primary forms, numerous endocrine diseases induce secondary dyslipidemias that substantially modify lipid metabolism and contribute to cardiometabolic risk. This Position Statement of the Nutrition Hormones and Metabolism Club of the Italian Society of Endocrinology (SIE) aims to provide an updated, evidence-based synthesis of the pathophysiology, biochemical profile, and clinical impact of dyslipidemias associated with endocrine disorders. A comprehensive review of current literature was performed, integrating epidemiological, mechanistic, and clinical data on lipid alterations across major endocrine diseases. Expert consensus was used to interpret evidence and formulate recommendations for clinical practice. Distinct and disease-specific dyslipidemic patterns were identified across conditions involving the hypothalamic-pituitary, thyroid, adrenal, gonadal, and GH/IGF-1 axes. Disorders such as acromegaly, growth hormone deficiency, hypothyroidism, hyperthyroidism, Cushing's syndrome, male and female hypogonadism, congenital adrenal hyperplasia, and polycystic ovary syndrome exhibit characteristic lipid abnormalities driven by hormonal dysregulation. These alterations contribute to increased cardiometabolic risk yet are frequently underrecognized and suboptimally managed. Early identification and tailored intervention may significantly improve outcomes. Endocrine-related dyslipidemias represent a clinically relevant but often overlooked contributor to cardiovascular risk. By summarizing current evidence and expert perspectives, this Position Statement aims to support clinicians in improving diagnosis, risk stratification, and management of lipid disorders associated with endocrine diseases, fostering a multidisciplinary approach to cardiometabolic prevention.Source: PubMed (PMID: 42171669)View Original on PubMed